EXDI - Exactus, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.0500
-0.1400 (-11.76%)
At close: 1:32PM EDT
Stock chart is not supported by your current browser
Previous Close1.1900
Open1.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.0500 - 1.1700
52 Week Range0.0480 - 4.0000
Volume8,732
Avg. Volume13,424
Market Cap36.153M
Beta (3Y Monthly)7.38
PE Ratio (TTM)N/A
EPS (TTM)-0.6520
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire18 days ago

    Exactus Inc. to Present at the 9th Annual LD Micro Invitational

    Exactus Inc. (EXDI) (the “Company”), a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, today announced that it will be presenting at the 9th Annual LD Micro Invitational on June 4th, 2019 at 10 AM PST / 1PM EST at the Luxe Sunset Bel Air Hotel in Los Angeles, California.  Phil Young, CEO of Exactus, Inc. will be presenting and meeting with investors throughout the day.

  • GlobeNewswirelast month

    Exactus One World, LLC. Digs in for Initial Cultivation of 200 Acres in Southwest Oregon

    Exactus Inc. (EXDI) (the “Company”), is intensifying its efforts to lead the industry in the hemp-derived Cannabidiol (CBD) market with the Company’s initial planting of seedlings in approximately 200 prime acres located in southwest Oregon on its Exactus One World (“EOW”) farms later this month. The Company is pleased to report the arrival of an independent fairness opinion from Scalar, LLC (“Scalar”)* highlighting EOW’s estimated enterprise value between approximately $55 million and $74 million, supporting a robust future of the growing organization.

  • GlobeNewswire2 months ago

    Exactus Initiates Operations on Two 100-Acre SW Oregon Industrial Hemp Farms

    Exactus Inc. (EXDI) (the “Company”), an emerging company pursuing seed to consumer opportunities in the hemp-derived Cannabidiol (CBD) market, is pleased to announce that it has received an independent fairness opinion from Scalar, LLC (“Scalar”) in connection with the Company’s acquisition of two operating farms located in Southwest Oregon, as reported in the Company’s March 11 press release. Scalar is a nationwide business valuation firm engaged in valuation services for tax, financial reporting, transaction advisory, and litigation consulting, which is regularly engaged in providing transaction advisory valuation services in connection with mergers and acquisitions.

  • GlobeNewswire2 months ago

    Exactus Applauds Executive Chairman, Jonathan Gilbert on Launch of Impact Biosciences Corp.

    Exactus Inc. (EXDI), a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, applauds its Executive Chairman of the Board, Jonathan Gilbert, on the launch of Impact Biosciences Corp. Jonathan Gilbert, cannabis industry veteran, and founder and former CEO of SOL Global Investments Corp. (CSE:SOL) (9SB.F) (SOLCF), whose wholly owned subsidiary, Scythian Biosciences Inc. (“SBI”), is seeking to list SBI as a new public company on the Canadian Stock Exchange (“CSE”) following a successful capital raise and spinout.

  • SOL Global to Spin Off Cannabinoid Drug Therapy Research and Development Subsidiary
    CNW Group2 months ago

    SOL Global to Spin Off Cannabinoid Drug Therapy Research and Development Subsidiary

    TORONTO , April 5, 2019 /CNW/ - SOL Global Investments Corp. ("SOL" or the "Company") (SOL.CN) (9SB.F) (SOLCF)  is pleased to announce that it intends to spin off its wholly-owned subsidiary, Scythian Biosciences Inc. ("SBI"), into an independent, publicly-traded company (the "Spin-off"). In connection with the Spin-off, SBI will be renamed "Impact Biosciences Corp" ("Impact") and will continue to pursue a drug development in the United States for the treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination drug candidate, which is being developed under contract with the University of Miami . Impact's mission is to become the first accepted drug regimen for concussive treatment.

  • GlobeNewswire3 months ago

    Exactus Acquires Hemp Healthy® Online Consumer and Healthcare Practitioner Brand with Full Traceability

    Exactus Inc. (OTCQB:EXDI / OTCQB:EXDID), a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products announced today it has agreed to acquire Hemp Healthy®, including www.buyhempcbd.com, where consumers can purchase a wide range of tinctures, topical lotions, creams and gel caps.

  • GlobeNewswire3 months ago

    Exactus Applauds CVS’s Decision to Sell CBD Products

    Exactus Inc. (OTCQB:EXDI / OTCQB:EXDID), a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products applauds CVS’s decision announced yesterday to begin selling CBD (cannabidiol) products in select stores throughout the country. Exactus believes that the best way for patients and their physicians to feel confident in their choice of CBD products is to purchase them from a trusted name with a proven track record.  There are many choices in the marketplace for CBD products, and it can be confusing for most consumers that are new to using CBD. Philip J Young, CEO, stated, “Our driving mission and philosophy at Exactus is to farm, process and manufacture quality products.  With the quality built into every product and tested to confirm that the potency, purity, and content that is on the label is indeed, exactly what is in the product.  We are happy to see a national icon such as CVS make a statement and begin selling CBD.

  • GlobeNewswire3 months ago

    Exactus Appoints Emiliano Aloi as President

    OTCQB:EXDID), a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products, announced it has appointed Emiliano Aloi as President. Philip J. Young, CEO of Exactus, stated: “We are excited to welcome Mr. Aloi as our President. A third-generation family farmer, Mr. Aloi is a pioneer in the space, and has been involved successfully in dozens of agroindustrial projects around the world over his career.

  • GlobeNewswire3 months ago

    CORRECTION - Exactus Announces Agricultural Diversification with Entry Into 200 Acre Farming Project for 2019 Grow Season – Promotion of Emiliano Aloi as President

    GLEN ALLEN, Va., March 11, 2019 -- This release corrects and replaces the version issued this morning at 6:30 AM ET. The complete and corrected release follows: Exactus Inc..

  • GlobeNewswire3 months ago

    Exactus Announces Agricultural Diversification with Entry Into 200 Acre Farming Project for 2019 Grow Season – Promotion of Emiliano Aloi as President

    GLEN ALLEN, Va., March 11, 2019 -- Exactus Inc. (OTCQB:EXDID), a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products, announced it has.

  • GlobeNewswire3 months ago

    Exactus Announces Stock Split

    Exactus Inc. (EXDI), a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products and point of care diagnostics, announced a reverse stock split of its shares of common stock at a ratio of 1-for-8. The purpose of the reverse stock split is to initiate the process of positioning the company for a future listing application to a national exchange. The reverse split will occur at the market open Monday, March 11, 2019, when Exactus Inc. common stock will begin trading on a split-adjusted basis.

  • GlobeNewswire3 months ago

    Exactus Announces Retirement of Remaining Convertible Notes

    Exactus Inc. (EXDI), a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, today announced that it has retired the last of its outstanding convertible notes. Each note was exchanged for shares of a new series of preferred stock designated as Series A Convertible Preferred Stock. As a result, the Company's convertible notes, which were convertible at variable prices reflecting a predetermined discount to market prices, have been retired and the Company has eliminated this form of indebtedness.

  • GlobeNewswire3 months ago

    Exactus Places $1 Million Purchase Order for CBD Products to Accelerate Near Term Growth

    Exactus Inc. (EXDI), a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, today announced it had placed an initial purchase order with Ceed2Med, LLC.  This first order consists of over 60 SKUs and represents the launch of our recently announced Master Product Development and Supply Agreement with Ceed2Med. Emiliano Aloi, who serves as senior advisor to Exactus from Ceed2Med, stated: “Exactus and Ceed2Med are developing a close link to prepare superior CBD products for the market.  We have begun to work closely with Exactus’ customers, launching a first line during February and are currently shipping samples of final product for approval.  Our design and development team at Ceed2Med provided sample and design assistance.  We anticipate that this first custom private label product will open doors to many more specialty stores through the customer’s existing distribution network of over 1,000 locations.

  • GlobeNewswire4 months ago

    Exactus Announces Inaugural Product Launch

    Exactus Inc. (EXDI), a healthcare company pursuing opportunities in hemp-derived, cannabidiol (CBD) products and point of care diagnostics, launched its first product and is pleased to announce the company has received its first purchase order. The company launched a 750mg full spectrum advanced absorption tincture and received its first purchase order from a customer in the health and nutritional medical space, a market vertical the company is currently focusing on building out, and one that Hemp Business Journal estimates will be the fastest growing market in the hemp-derived CDB space over the next four years. Philip Young, CEO of Exactus said, “We are in the early stages of transitioning into a leader in the CBD market sector.

  • GlobeNewswire4 months ago

    Exactus to Attend 15th Annual PDS Super Conference

    Exactus Inc. (EXDI), a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products and point of care diagnostics, announced the Company will attend the 15th Annual PDS Super Conference in Orlando Florida. Philip Young, CEO of Exactus said, “The 15th Annual PDS Super Conference is the perfect venue for Exactus to introduce itself to an expansive group of decision makers as we look to build out our healthcare practitioner distribution network. Exactus, Inc., is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, Cannabidiol, which is more commonly referred to as CBD.

  • ACCESSWIRE4 months ago

    Exactus Appoints John Price as Independent Director and Chairman of the Audit Committee

    GLEN ALLEN, VA / ACCESSWIRE / February 13, 2019 / Exactus Inc. (EXDI), a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products and point of care diagnostics, is pleased to announce the appointment of John Price to the Board of Directors and Chairman of the Audit Committee. Mr. Price currently serves as Chief Financial Officer of SCWorx Corp., (WORX), provider of data normalization, application interoperability and big data analytics within the healthcare provider market, where he has been since 2016.

  • ACCESSWIRE4 months ago

    Exactus Appoints Seasoned Industry Veteran Jonathan Gilbert As Executive Chairman of the Board

    GLEN ALLEN, VA / ACCESSWIRE / February 12, 2019 / Exactus Inc. (EXDI) a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products and point of care diagnostics, is pleased to announce the appointment of Jonathan Gilbert to the newly created position of Executive Chairman.

  • ACCESSWIRE4 months ago

    Exactus Releases Annual Shareholder Letter

    Over the last several months the Exactus team and its advisors have been evaluating numerous opportunities and relationships to increase shareholder value. This decision was based in part on the passing of The Hemp Farming Act of 2018. The Brightfield Group, an industry leading market research firm, estimates the total CBD market to be ~$22B in 2022.

  • ACCESSWIRE5 months ago

    Exactus Inc. Announces Retirement of Convertible Notes

    GLENN ALLEN, VA / ACCESSWIRE / January 30, 2019 / Exactus Inc. (EXDI) a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products and point of care diagnostics, is pleased to announce that it has reached agreement with the holders of its currently convertible notes to retire those notes. The Company agreed to issue a new series of preferred stock designated as Series A Convertible Preferred Stock in place of the notes. As a result, the Company's convertible notes which had been currently convertible at variable prices reflecting a predetermined discount to market prices, have been retired and the Company has eliminated this indebtedness.

  • ACCESSWIRE5 months ago

    Exactus Appoints New Members to Its Board of Directors

    GLEN ALLEN, VA / ACCESSWIRE / January 25, 2019 / Exactus Inc. (EXDI) a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products and point of care diagnostics, is pleased to announce the election of three new board members including Kevin Esval, Jeffrey Thompson and Ken Puzder. With these three additions, the Exactus Board of Directors expands to five.

  • ACCESSWIRE5 months ago

    Exactus Inc. Announces Entry into Hemp CBD Market

    GLEN ALLEN, VA / ACCESSWIRE / January 17, 2019 / Exactus Inc. (EXDI) is pleased to announce its entrance into the CBD market in conjunction with Ceed2Med, LLC's ("C2M") acquisition of a controlling ownership interest in Exactus, Inc. and a Master Product Development and Supply Agreement with Ceed2Med, LLC for hemp-based Cannabidiol ("CBD") products with full genetic traceability. Exactus has a number of hemp-based CBD products in the pipeline and expects to offer tinctures, edibles, capsules, topical solutions and animal health products manufactured by C2M commencing the first quarter of 2019.